Abstract. Although *Radix clematidis* has commonly been used in Chinese medicine for the treatment of arthralgia, the anti-diabetic effects of *Radix clematidis* have not yet been reported. In the present study, we demonstrated that *Radix clematidis* extract (RCE) could prevent cytokine-induced ß-cell damage and streptozotocin (STZ)-induced diabetes in mice. Treatment of RINm5F insulinoma cells with interleukin-1ß and interferon-γ reduced cell viability; however, RCE protected the cells from this cytokine-mediated viability reduction in a concentration-dependent manner. Additionally, incubation with RCE resulted in a significant suppression of cytokine-induced nitric oxide (NO) production, which was correlated with reduced levels of the inducible form of NO synthase (iNOS) mRNA and protein. The molecular mechanism by which RCE inhibited iNOS gene expression appeared to involve inhibition of NF-κB activation. Furthermore, RCE abolished the cytokine-induced increases in NF-κB binding activity and p65 subunit levels in the nucleus, as well as IκBα degradation in the cytosol when compared to unstimulated cells. The protective effect of RCE was further demonstrated by the observed suppression of NF-κB-dependent iNOS expression and normal insulin secreting responses to glucose in cytokines-treated islets. The anti-diabetic effect of RCE was even more striking in vivo, where nearly complete protection against STZ-induced diabetes was observed. Treatment of mice with STZ resulted in hyperglycemia and hypoinsulinemia, which was further evidenced by immunohistochemical staining; however, pretreatment of mice with RCE blocked the destruction of STZ-induced islets and the development of type 1 diabetes.

Introduction

Type 1 diabetes mellitus is an autoimmune disease that causes selective destruction of insulin producing ß cells in the Langerhans islets (1). During early stages of the disease, histological findings show features of insulitis, which is characterized by the infiltration of immune cells such as T lymphocytes, macrophages, and natural killer cells into the pancreatic islets (2,3). These cells produce and release various cytokines that act as humoral mediators of the immunologic process. Therefore, cytokines such as interleukin-1ß (IL-1ß), tumor necrosis factor-α, and interferon-γ (IFN-γ) have been implicated as key effector molecules in ß-cell function and viability (4).

IL-1ß alone or in combination with tumor necrosis factor-α or IFN-γ causes the production of excess nitric oxide (NO) in pancreatic islets (5,6). NO is produced by the oxidation of L-arginine to L-citruline by nitric oxide synthase (NOS), and excess NO may inhibit mitochondrial metabolism, modify protein, and cleave DNA (7,8). It has also been reported that streptozotocin (STZ), a commonly used diabetogenic agent, produces NO (9,10). Several studies have been conducted to evaluate the possible role of NO in the pathogenesis of autoimmune diabetes, the results of which have demonstrated that nuclear factor κB (NF-κB)-dependent NO production plays a key role in the dysfunction and destruction of ß cells.
The production of NO is regulated by transcription factors that bind to specific sites in the promoter of the inducible form of the NOS (iNOS) gene. Transcriptional NF-κB, which can be activated by cytokines and streptozocin, has been implicated as a key signaling mediator of the induction of iNOS (11-13). NF-κB is initially located in the cytoplasm as an inactive form complexed with IκB, an NF-κB inhibitory factor. However, various inducers cause this complex to dissociate, presumably via the phosphorylation of IκB, thereby allowing NF-κB to be released from the complex. NF-κB then translocates to the nucleus, where it interacts with its DNA recognition sites to mediate gene transcription (14,15).

Radix clematidis is the name given to the root of Clematis florida T enorma, a member of the Ranunculaceae family. Radix clematidis is commonly used in traditional Chinese medicine to alleviate joint pain and relieving swelling. In the present study, we evaluated the preventive effects of Radix clematidis extract (RCE) on cytokine- and STZ-induced pancreatic β-cell damage both in vitro and in vivo. RCE was found to block the cytokine- and STZ-induced NF-κB pathway, thereby protecting the pancreatic β cells. These results indicate that Radix clematidis may be useful as an anti-diabetic agent.

Materials and methods

Cell culture. RINm5F (RIN) cells were purchased from the American Type Culture Collection and grown at 37°C under a humidified, 5% CO2 atmosphere in RPMI-1640 medium (HyClone, South Logan, UT) supplemented with 10% fetal bovine serum and 2 mM glutamine, 100 U/ml of penicillin, 100 μg/ml of streptomycin, and 2.5 μg/ml of amphotericin B.

Preparation of Radix clematidis extract. Radix clematidis was purchased from Wonkwang Oriental Medical Hospital in Iksan, Jeonbuk, Korea and its identity was confirmed by Ho-Joon Song, keeper of the Herbarium. Voucher samples were preserved for reference in the Herbarium of the Department of Physiology, School of Oriental Medicine, Wonkwang University (Omphy, 2005-58). Radix clematidis (200 g) was then ground and extracted in boiling water for 4 h. The extract was centrifuged at 3,000 x g for 20 min, after which the supernatant was concentrated to 200 ml under reduced pressure and then freeze dried to 20.4 g. The sterile extract was stored at -70°C until use.

MTT assay for cell viability. The viability of cultured cells was determined by assessing the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan. Briefly, the cells were treated with cytokine for 24 or 48 h, after which they were washed twice with PBS, and MTT (100 μg/100 μl of PBS) was added. The cells were incubated at 37°C for 1 h, after which DMSO (100 μl) was added to dissolve the formazan crystals. The absorbance was measured at 570 nm using a spectrophotometer.

5-Bromo-2-deoxyuridine (BrdU)-labeling cell proliferation assay. A cell proliferation enzyme-linked immunosorbant assay (BrdU kit; Amersham Biosciences, Piscataway, NJ) was used to measure the incorporation of BrdU during DNA synthesis following the manufacturer's protocols. Briefly, following treatment with cytokines for 24 h or 48 h, BrdU (10 μM) was added to the culture medium for 2 h. The BrdU-labeled cells were fixed, after which the DNA was denatured in fixative solution for 30 min at room temperature. The cells were then incubated with peroxidase-conjugated anti-BrdU antibody for 2 h at room temperature, followed by washing three times with washing solution. The immune complex was detected by inducing a 3,3',5,5'-tetramethylbenzidine substrate reaction and measuring the absorbance at 405 nm.

NO measurement. Biologically produced NO is rapidly oxidized to nitrate and nitrite in aqueous solutions (16). Therefore, NO production was evaluated by measuring the nitrite concentrations in the cell-free culture supernatant using a colorimetric assay. Following treatment with cytokines for 24 h, 100 μl aliquots of the culture supernatants were incubated with 100 μl of a modified Griess reagent (1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride in 60% acetic acid) at room temperature for 5 min. The absorbance at 540 nm was measured using a spectrophotometer. Next, the concentrations of NO were determined using a linear standard curve generated from serial dilutions of sodium nitrite in working medium.

RNA isolation and real-time PCR for iNOS. Total RNA was isolated from RIN cells or islets using TRIzol reagent (Invitrogen, Carlsbad, CA). Briefly, RNA was precipitated with isopropanol and dissolved in DEPC-treated distilled water. The total RNA (2 μg) was treated with RNase-free DNase (Invitrogen), and first-strand cDNA was generated using the random hexamer primer provided in the first-strand cDNA synthesis kit (Applied Biosystems, Foster City, CA). The specific primers for iNOS were designed using primer express software (Applied Biosynthesis): iNOS (accession no. NM_012611), 5'-TGTTGCTATGCGGAAGGTCAT-3' (forward), and 5'-CGACTTTCCTGGTCAGTACCAA-3' (reverse). The sequence for the control 18S ribosomal RNA was purchased from Applied Biosystems and used as the invariant control. The real-time PCR reaction, which was contained in a final volume of 10 μl, consisted of 10 ng of reverse transcribed total RNA, forward and reverse primers at a concentration of 167 nM and 2X PCR master mixture. The PCR reaction was conducted in 384-well plates using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). All reactions were conducted in triplicate.

Western blot analysis. Cells or islets were homogenized in 100 μl of ice-cold lysis buffer (20 mM HEPES, pH 7.2, 1% Triton X-100, 10% glycerol, 1 mM PMSF, 10 μg/ml leupeptin, and 10 μg/ml aprolatin). The homogenates, which contained 20 μg of protein, were then separated by SDS-PAGE with 7.5% (for iNOS) or 12% resolving (for IκBα, p65, B-actin, and PCNA) and 3% acrylamide stacking gels, and then transferred to nitrocellulose sheets. Next, the nitrocellulose paper was blocked with 2% bovine serum albumin and then incubated for 4 h with 1 μg/ml of primary antibody (Santa Cruz Biochemicals, Santa Cruz, CA). Horseradish peroxidase-conjugated IgG (Zymed, South San Francisco, CA) was used as a secondary antibody. Protein expression
levels were then determined by analyzing the signals captured on the nitrocellulose membranes using a Chemi-doc image analyzer (Bio-Rad, Hercules, CA).

Preparation of nuclear extracts. After treatment with cytokines or STZ, cells or pancreatic tissues were homogenized, washed twice with ice-cold PBS (pH 7.9), and pelleted at 12,000 x g for 30 sec. The pellet was suspended in cold hypotonic lysis buffer (10 mM HEPES, 1.5 mM MgCl₂, 0.2 mM KCl, 0.2 mM PMSF, and 0.5 mM dithiothreitol), vortexed for 10 sec, and incubated on ice for 15 min. The packed cells were resuspended in ice-cold hypotonic lysis buffer in the presence of 50 μl of 10% Nonidet P-40, and incubated on ice for 25 min. Next, the nuclear fraction was precipitated by centrifugation at 13,000 x g for 1 min at 4°C, and the supernatants (cytosol extracts) were collected and stored at -80°C. The pelleted nuclei were resuspended in 50-100 μl of low salt extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 25% glycerol, 20 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 mM dithiothreitol), added to an equal volume of high salt extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 25% glycerol, 80 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 mM dithiothreitol) in a drop-wise fashion, and incubated under continuous shaking at 4°C for 45 min. The sample was centrifuged for 20 min at 12,000 x g. Aliquots of the nuclear extracts were stored at -80°C, and the protein concentration was determined.

Electrophoretic mobility shift assay (EMSA). The activation of NF-κB was assayed by a gel mobility shift assay using nuclear extracts from control and treated cells. An oligonucleotide containing the κ-chain binding site (αx, 5′-CCGG TTACACAGAGGGGGCTTTCCGAG-3′) was synthesized and used as a probe for the gel retardation assay. The two complementary strands were annealed and labeled with [α-32P]-dCTP. Labeled oligonucleotides (10,000 cpm), 10 μg of nuclear extracts and binding buffer (10 mM Tris-HCl, pH 7.6, 500 mM KCl, 10 mM EDTA, 50% glycerol, 100 ng poly(dI- dC), 1 mM dithiothreitol) were incubated for 30 min at room temperature in a final volume of 20 μl. Next, the reaction mixtures were analyzed by electrophoresis on 4% polyacrylamide gels in 0.5X Tris-borate buffer, and the gels were dried and examined by autoradiography.

Isolation of islets and insulin secretion assay. Pancreatic islets were isolated from male Sprague-Dawley rats using the collagenase digestion method, as described previously (17). Briefly, after treatment with cytokines for 24 h, the islets were washed three times in Krebs-Ringer bicarbonate buffer (25 mM HEPES, 115 mM NaCl, 24 mM NaHCO₃, 5 mM KCl, 1 mM MgCl₂, 2.5 mM CaCl₂, and 0.1% bovine serum albumin, pH 7.4) containing 3 mM D-glucose, and insulin secretion was then measured by static incubation of the islets for 30 min in the presence of either 5.5 or 20 mM D-glucose. The insulin content of the medium was then determined by ELISA (Linco Research, St. Charles, MO).

Type 1 diabetes induction. Specific pathogen-free male ICR mice were purchased from Orientbio Inc. (Seoungnam, Korea) and housed at our animal facility for one week prior to use. All mice used were 5-6-weeks old and were kept under specific pathogen-free conditions with free access to a standard commercial diet. To induce diabetes, mice were injected with 100 mg of STZ/kg of body weight dissolved in 0.1 M sodium citrate buffer (pH 4.0) via a tail vein. All injections of STZ were administered within 5 min of the treatment being prepared. Mice were administered 250 mg/kg RCE orally daily for three days before being administered the STZ injections. To determine the effects of RCE, mice were divided into the following groups: i) the non-treated control group, ii) the STZ group, iii) the RCE group, and 4) the RCE + STZ group (n=5, each group). The day on which the first STZ injection was administered is defined as day 1. Control group animals were administered citrate buffer alone. At day 5, the mice were sacrificed by decapitation without anesthesia and trunk blood was collected in prechilled tubes containing 1 mg/ml of EDTA for insulin and glucose determinations. The plasma glucose concentration was assayed by the glucose oxidase method (Sigma, St. Louis, MO), and the plasma insulin concentration was measured using an ELISA kit. All experimental procedures were approved by the Institutional Animal Care and Use Committee at Chonbuk National University.

Immunohistochemistry. For immunohistochemical staining, the Dako Envision system (Dako, Carpinteria, CA), which used dextran polymers conjugated with horseradish peroxidase, was employed to avoid any endogenous biotin contamination. Briefly, the pancreases were removed and immediately placed in fixative (10% formalin solution in 0.1 M PBS). Histologic sections 4-μm thick were cut from the formalin-fixed paraffin-embedded tissue blocks. After deparaffinization, the tissue sections were treated using a microwave antigen retrieval procedure in 10 mM sodium citrate buffer. The sections were blocked with endogenous peroxidase, after which they were incubated with Protein Block Serum-Free (Dako) to block non-specific staining. Next, the sections were incubated with anti-insulin antibody (Santa Cruz Biochemicals), and the peroxidase activity was detected using the enzyme substrate 3-amino-9-ethyl carbazole.

Statistical analysis. Statistical analyses of the data were performed using ANOVA and Duncan's test. Differences with a p<0.05 were considered statistically significant.

Results

Prevention of cytokine-induced viability reduction by RCE. Based on the results of a previous study (18), a cytokine mix consisting of IL-1β (5 ng/ml) and IFN-γ (100 U/ml) was employed throughout the current study to maintain a stable toxic effectiveness. RIN cells from a rat pancreatic β-cell line were cultured to near confluence and then pretreated with or without RCE for 3 h. These cells were exposed to cytokines for 24 h or 48 h and their viability was assessed by an MTT assay. Treatment with cytokines significantly reduced the cell viability to 46.4±0.7% and 19.6±0.4% of that of the control at 24 and 48 h, respectively (Fig. 1, upper panel). Conversely, RCE increased the viability of cytokine-treated RIN cells in a concentration-dependent manner. The protective effect of RCE on cytokine-induced viability change was
further confirmed by evaluating BrdU incorporation in RIN cells. BrdU is a thymidine analog that is incorporated into proliferating cells during DNA synthesis; thus it reflects the proliferative potential of the cells. Cytokines reduced the level of BrdU incorporation to 58.2±0.3 and 44.5±0.4% of the control levels at 24 and 48 h, respectively, indicating that cytokines reduced proliferation. Similar to the results of the MTT assay, RCE was found to prevent the cytokine-mediated decrease in cell proliferation potential in a concentration-dependent manner (Fig. 1, lower panel). It should be noted that treatment with the tested concentrations of RCE alone did not affect the viability of RIN cells (data not shown).

**Effect of RCE on IL-1ß and IFN-γ-induced NO production and iNOS expression.** It has been reported that cytokine-mediated destruction of β cells is caused by an increase of NO production (5,6). Incubation of RIN cells with cytokines for 24 h resulted in significant production of nitrite (a stable oxidized product of NO) by these cells (Fig. 2); however, the presence of RCE diminished the cytokine-mediated NO production, which was well correlated with their increased viability. To examine whether RCE inhibits NO production via suppression of iNOS gene expression, the changes in iNOS mRNA and protein expression were investigated by real-time PCR and Western blotting, respectively. The iNOS mRNA and protein expressions were markedly increased in cells treated with cytokines, whereas cells pretreated with RCE showed suppression of the cytokine-induced iNOS expression at both the mRNA and protein levels (Fig. 2).

**Effect of RCE on IL-1ß and IFN-γ-induced NF-κB activation.** NF-κB has been implicated in the transcriptional regulation of cytokine-induced iNOS expression. Therefore, we studied the effect of RCE on cytokine-stimulated activation of the NF-κB pathway in RIN cells. Cytokine-treated RIN cells showed increased binding activity toward an NF-κB consensus sequence (Fig. 3A), as well as increased p65 subunit levels in their nuclei and IκBα degradation in their cytosol (Fig. 3B) when compared to unstimulated cells. Additionally, cytokine-induced NF-κB activation was markedly suppressed by pretreatment with RCE, which suggests that RCE inhibits iNOS expression through inhibition of NF-κB activation. The specificity of the DNA-protein interaction for NF-κB was demonstrated by performing competition assays using a 50-fold excess of unlabeled oligonucleotide (Fig. 3A, lane 7).

**Suppression of the cytokine-induced NF-κB pathway and preservation of glucose-stimulated insulin secretion (GSIS) by RCE in rat islets.** We further assayed the preventive effects of RCE using rat pancreatic islets isolated from the male Sprague-Dawley rat to support the physiological importance of the results observed in the cell line studies. Incubation of rat islets for 24 h with cytokines resulted in a 2.8-fold increase in NO production (Fig. 4A). Additionally, real-time PCR and Western blotting revealed that iNOS mRNA and protein levels were markedly increased in response to treatment with cytokines (Fig. 4A). In addition, similar to the results
obtained using the RIN cells, pretreatment of the islets with RCE abolished the effects of cytokines and reduced the NO production and iNOS expression to the control levels. Treatment with cytokines also increased the NF-κB DNA binding activity in islets (Fig. 4B); however, pretreatment of the islets with RCE completely abolished the effects of cytokines. To add functional data, we determined whether RCE could protect against cytokine-induced impairment of GSIS. After 24 h of exposure to the cytokines, insulin secretion was assayed in response to 20 mM glucose. Control islets secreted insulin at a concentration of 20.3±1.1 ng/ml, whereas insulin secretion from cytokine-treated islets decreased significantly to 10.9±0.9 ng/ml (p<0.01) (Fig. 4C). However, pretreatment with RCE blocked the effect of the cytokines and restored the islet cell insulin secretion to levels obtained using the RIN cells, pretreatment of the islets with RCE abolished the effects of cytokines and reduced the NO production and iNOS expression to the control levels. Treatment with cytokines also increased the NF-κB DNA binding activity in islets (Fig. 4B); however, pretreatment of the islets with RCE completely abolished the effects of cytokines. To add functional data, we determined whether RCE could protect against cytokine-induced impairment of GSIS. After 24 h of exposure to the cytokines, insulin secretion was assayed in response to 20 mM glucose. Control islets secreted insulin at a concentration of 20.3±1.1 ng/ml, whereas insulin secretion from cytokine-treated islets decreased significantly to 10.9±0.9 ng/ml (p<0.01) (Fig. 4C). However, pretreatment with RCE blocked the effect of the cytokines and restored the islet cell insulin secretion to levels obtained using the RIN cells, pretreatment of the islets with RCE abolished the effects of cytokines and reduced the NO production and iNOS expression to the control levels. Treatment with cytokines also increased the NF-κB DNA binding activity in islets (Fig. 4B); however, pretreatment of the islets with RCE completely abolished the effects of cytokines. To add functional data, we determined whether RCE could protect against cytokine-induced impairment of GSIS. After 24 h of exposure to the cytokines, insulin secretion was assayed in response to 20 mM glucose. Control islets secreted insulin at a concentration of 20.3±1.1 ng/ml, whereas insulin secretion from cytokine-treated islets decreased significantly to 10.9±0.9 ng/ml (p<0.01) (Fig. 4C). However, pretreatment with RCE blocked the effect of the cytokines and restored the islet cell insulin secretion to levels
similar to that of the control. RCE itself did not affect the insulin secreting response to glucose.

**Effect of RCE on the STZ-induced type 1 diabetes model.** To assess the potential of RCE to protect against STZ-mediated type 1 diabetes, ICR mice were injected with a single high dose of STZ with or without a previous injection of RCE. The results revealed a striking resistance to the development of diabetes following STZ injection in RCE-pretreated mice when compared with untreated controls. As expected, mice that received STZ became hyperglycemic and hypoinsulinemic at 72 h. The blood glucose and insulin levels of these mice at day 5 were 249.4±17.7 mg/dl and 1.4±0.1 ng/ml, respectively, which is well within the acceptable diabetic range. Conversely, mice that were pretreated with RCE and then treated with STZ showed normal blood glucose and insulin values (Fig. 5A). Next, pancreatic islets were histologically examined. Pancreatic tissues were obtained 5 days after STZ administration with or without RCE pretreatment and then subjected to H-E staining and immunohistochemistry. In STZ-injected mice, the most consistent findings in pancreatic sections stained with H&E were degenerative and necrotic changes in β cells (Fig. 5B, b). In addition, immunohistochemical staining showed weak insulin-reactivity (Fig. 5B, f). However, H&E staining and immunohistochemistry revealed that diabetic mice pretreated with RCE had near-normal islets (a well marginated and round shape with strong insulin positivity in islet β cells) (Fig. 5B, d and h). Finally, potential mechanisms involved in the beneficial effect of RCE on STZ toxicity were investigated. As shown in Fig. 5C, STZ treatment rapidly increased the level of NF-κB DNA binding (Fig. 5C) in the pancreas, whereas pretreatment with RCE completely inhibited STZ-induced NF-κB activation, suggesting that suppression of the NF-κB
pathway may be a potential mechanism involved in the anti-diabetic effect of RCE on STZ toxicity.

Discussion

The results of this study demonstrated that RCE exerts anti-diabetic effects on pancreatic β cells that have been challenged with cytokines or STZ. RCE was found to prevent both forms of cytokine-induced β-cell death in RIN cells and primary rat islets. Furthermore, the results of this study demonstrated that RCE had protective effects against the development of type 1 diabetes induced by STZ. Additionally, this study demonstrated that the preventive actions of RCE on cytokines and STZ toxicity were associated with suppression of the NF-κB pathway.

In pancreatic β cells, inhibition of iNOS has been shown to prevent apoptosis, which indicates that increased NO production due to NF-κB activation is an important signal in cytokine-induced apoptosis (19-21). Therefore, the process leading to the production of NO in response to treatment with cytokines and suppression of this process by RCE were investigated in this study. When analyzing the NF-κB binding activity in cytokine-treated RIN cells, a clear increase in the specific band intensity was observed, whereas attenuation was observed in cells that had been pretreated with RCE. In addition, treatment of RIN cells with RCE prior to stimulation by cytokines resulted in inhibition of IκBα degradation and parallel translocation of p65 into the nucleus, which suggests that RCE acts upstream from IκBα degradation. Although the upstream signaling pathway leading to IκBα restoration by RCE is not clear, our results are in agreement with those of a recent study that found Ad-IκBα (S32A, S36A), a non-degradable IκBα mutant, to be effective at preventing cytokine toxicity (13). Even though most of the experiments described here were conducted on RIN cells, the observed phenomena are not unique to this type of cell because similar protection against cytokines toxicity has also been observed in isolated rat islets. Therefore, we believe that the phenomenon described in this article also applies to other insulinoma cells and pancreatic islets.

NF-κB governs both proinflammatory and antiapoptotic responses according to the modes of insults in β-cells. For example, NF-κB regulates the expression of multiple proinflammatory genes that contribute to islet destruction such as Fas, iNOS and cyclooxygenase-2 (6,13,22). In addition, the promoters of other proinflammatory genes induced in β cells, including chemokines and adhesion molecules, also possess binding elements for NF-κB (23). The importance of NF-κB in β-cell damage is underscored by the fact that inhibition of NF-κB activation or translocation prevents IL-1β and IFN-γ-induced β-cell dysfunction and death both in vitro and in vivo (11-13). Conversely, it is also known that NF-κB has a defensive and protective role (13). For example, NF-κB limited the tissue damage in a cerulein-induced acute pancreatitis model, whereas blocking NF-κB activation had an adverse effect by increasing apoptosis, thereby causing more tissue damage (24). NF-κB regulates apoptosis by controlling the expression of multiple anti-apoptotic genes including the inhibitor of apoptosis protein (IAP) and A20 (25,26). Blockade of NF-κB via the use of an IκBα super-repressor also sensitized β cells to TNF-α-mediated apoptosis (27). Therefore, it remains unclear whether NF-κB activation in the pancreas is protective or detrimental.

We used the STZ-induced diabetes model to study the role of NF-κB in vivo. RCE completely blocked the type 1 diabetes that develops in response to STZ, and this was paralleled by a preserved β-cell mass. STZ destroys β cells and causes diabetes by inducing DNA alkylation (28). In addition, the diabetic effects of STZ may also be a result of the NO release (9,10). It has been reported that systemic p50 or c-RelA null mice are resistant to STZ (29,30), which supports the importance of the NF-κB pathway in STZ-induced diabetes development. Following injection with STZ, pancreatic islets showed obvious β-cell damage with degenerative and necrotic changes to β cells and reduced staining for insulin. We also observed an increase in the activation of NF-κB in the pancreas of STZ-treated mice, and the ability of RCE to protect against the development of type 1 diabetes was correlated with its ability to inhibit NF-κB activation. Therefore, it is possible that the RCE-induced suppression of NF-κB activation is crucial for its protective effects to occur.

In conclusion, we showed herein that RCE protects β cells against cytokines or STZ, thereby maintaining the insulin secretion capacity of islets. Recent success in islet transplantation has focussed attention on cell-based insulin replacement strategies for the treatment of type 1 diabetes. However, limited tissue supply and concerns regarding the life-long administration of immunosuppressive agents may limit the applicability of this approach (31). The beneficial effect of RCE on β cells may lead to therapeutic and preventive approaches aimed at enhancing the survival of β cells, thereby reducing or delaying cytokine-mediated β-cell destruction.

Acknowledgements

This work was supported by the Regional Research Centers Program of the Korean Ministry of Education & Human Resources Development through the Center for Healthcare Technology Development and by a grant from the Ministry of Science & Technology (MoST)/Korea Science & Engineering Foundation (KOSEF) through the Vestibulocochlear Research Center (VCRC) at Wonkwang University (R13-2002-055-0000-0).

References


